Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
11 Jul 2019
Historique:
received: 26 02 2019
accepted: 22 05 2019
entrez: 18 7 2019
pubmed: 18 7 2019
medline: 18 7 2019
Statut: epublish

Résumé

Protein arginine methyltransferase 5 (PRMT5) is known to symmetrically dimethylate numerous cytosolic and nuclear proteins that are involved in a variety of cellular processes. Recent findings have revealed its potential as a cancer therapeutic target. PRMT5 possesses a cysteine (C449) in the active site, unique to PRMT5. Therefore, covalent PRMT5 inhibition is an attractive chemical approach. Herein, we report an exciting discovery of a series of novel hemiaminals that under physiological conditions can be converted to aldehydes and react with C449 to form covalent adducts, which presumably undergo an unprecedented elimination to form the thiol-vinyl ethers, as indicated by electron density in the co-crystal structure of the PRMT5/MEP50 complex.

Identifiants

pubmed: 31312404
doi: 10.1021/acsmedchemlett.9b00074
pmc: PMC6627734
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1033-1038

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Mol Cell Biol. 2004 Nov;24(21):9630-45
pubmed: 15485929
J Biol Chem. 2009 Aug 7;284(32):21347-59
pubmed: 19520849
Chembiochem. 2010 Jun 14;11(9):1219-23
pubmed: 20480486
BMC Bioinformatics. 2010 Jul 23;11:396
pubmed: 20653935
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):17960-5
pubmed: 23071334
Nat Rev Cancer. 2013 Jan;13(1):37-50
pubmed: 23235912
J Med Chem. 2015 Feb 26;58(4):1596-629
pubmed: 25406853
Cell Mol Life Sci. 2015 Jun;72(11):2041-59
pubmed: 25662273
Nat Chem Biol. 2015 Jun;11(6):432-7
pubmed: 25915199
Drug Discov Today. 2015 Sep;20(9):1061-73
pubmed: 26002380
Epigenomics. 2015;7(8):1327-38
pubmed: 26646500
Cancer Discov. 2016 Mar;6(3):316-29
pubmed: 26739882
Expert Opin Investig Drugs. 2016;25(3):335-58
pubmed: 26789238
Science. 2016 Mar 11;351(6278):1214-8
pubmed: 26912360
Science. 2016 Mar 11;351(6278):1208-13
pubmed: 26912361
Cell Rep. 2016 Apr 19;15(3):574-587
pubmed: 27068473
Mol Cell. 2017 Jan 5;65(1):8-24
pubmed: 28061334
Chem Rev. 2018 Feb 14;118(3):989-1068
pubmed: 28338320
Curr Opin Chem Biol. 2017 Aug;39:100-108
pubmed: 28662389
Future Med Chem. 2017 Nov;9(17):2081-2098
pubmed: 29076773
J Med Chem. 2018 Nov 8;61(21):9429-9441
pubmed: 29870258
ACS Med Chem Lett. 2018 Apr 23;9(7):612-617
pubmed: 30034588
Bioorg Med Chem Lett. 2019 Jun 1;29(11):1264-1269
pubmed: 30956011
Biochemistry. 1982 Mar 2;21(5):1028-32
pubmed: 7074045

Auteurs

Hong Lin (H)

Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.

Min Wang (M)

Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.

Yang W Zhang (YW)

Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.

Shuilong Tong (S)

VIVA Biotech Ltd., 334 Aidisheng Road, Zhangjiang High-Tech Park, Shanghai 201203, China.

Raul A Leal (RA)

Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.

Rupa Shetty (R)

Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.

Kris Vaddi (K)

Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.

Juan I Luengo (JI)

Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.

Classifications MeSH